Adomeglivant

N/A

Report date: 2024/08/13 15:18:38
NME

Base Information

Drug NameAdomeglivant
Drug Alias NameLY-240902174Z5ZL2KVG
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor antagonists
TargetsGlucagon receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Kidney Failure, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[15] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Kidney Failure, Chronic +[4] 

Other Information

ATC CodeN/A
Related LinksN/A